{"entity":{"id":"nct06998173","kind":"trial","name":"Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor","aka":[],"tldr":"A phase 1 trial of DAT-1604 run by Danatlas Pharmaceuticals Co., Ltd, not yet recruiting.","summary":"Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor is a phase 1 interventional study registered as NCT06998173 by Danatlas Pharmaceuticals Co., Ltd, with 228 participants planned, started 2025-07-31. Conditions recorded: Advanced Solid Tumors. Interventions recorded: DAT-1604 tablet.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06998173","url":"https://clinicaltrials.gov/study/NCT06998173"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["dat-1604"],"companies":["danatlas-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06998173","phase":"1","setting":"Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DAT-1604 Tablets as Monotherapy in the Advanced Solid Tumor","sponsor":"Danatlas Pharmaceuticals Co., Ltd","enrolled":228,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06998173/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"dat-1604","kind":"drug","name":"DAT-1604","route":"/drugs/dat-1604/"}],"company":[{"id":"danatlas-pharmaceuticals","kind":"company","name":"Danatlas Pharmaceuticals","route":"/companies/danatlas-pharmaceuticals/"}]}}